萊姆病檢測市場機會、成長動力、產業趨勢分析與預測 2025 - 2034

預計全球萊姆病檢測市場規模將在 2024 年達到 67 億美元，預計 2025 年至 2034 年期間的複合年成長率為 5.7%。人們越來越意識到未經治療的萊姆病會產生嚴重的長期影響，例如神經系統和肌肉骨骼併發症，這推動了對早期診斷和及時治療的需求，從而進一步擴大了市場。

診斷技術的重大進步，包括即時診斷（POC）測試和家用測試套件的廣泛採用，正在重塑市場。這些創新的解決方案提供了快速、方便的診斷選項，促進早期發現和干涉，並鼓勵個人儘早採取行動。政府和衛生組織支持的公共衛生措施和教育活動對於提高人們的認知和提倡定期檢測至關重要。此外，蜱傳疾病研究資金的不斷增加也推動了創新並促進了市場進一步成長。

在診斷技術方面，市場分為幾個部分，包括血清學檢測、核酸檢測、淋巴細胞轉化檢測、尿液抗原檢測和免疫螢光染色。血清學測試領域預計將經歷最高的成長，預計複合年成長率為 6.2%，到 2034 年將產生 50 億美元的產值。酵素連結免疫吸附試驗 (ELISA) 和蛋白質印跡法等測試對檢測伯氏疏螺旋體抗體非常有效，確保其作為萊姆病檢測最廣泛使用和最值得信賴的方法的地位。

市場也按樣本類型分類，包括血液、尿液、腦脊髓液 (CSF) 和其他基於血液的樣本。 2024 年，血液樣本部分佔據 52.2% 的市場佔有率，預計在整個預測期內將保持其主導地位。血液樣本被認為是萊姆病檢測的黃金標準，因為它們在檢測抗體和細菌 DNA 方面具有很高的準確度。這使得它們成為臨床和實驗室環境的首選，提供簡單、非侵入性的診斷方法。

在美國，萊姆病檢測市場價值將於 2024 年達到 26 億美元，預測期內將強勁成長。萊姆病發生率高，加上氣候變遷和蜱蟲活動增加導致的地理分佈廣泛，推動了對檢測服務的需求。在衛生組織的支持下，公眾意識的不斷增強正在鼓勵人們採取更積極主動的方式進行萊姆病篩檢。因此，醫療保健提供者越來越重視萊姆病檢測，特別是在高風險地區，從而促進該地區市場的持續成長。

目錄

第 1 章：方法論與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 萊姆病患病率不斷上升
    • 診斷技術的進步
    • 家庭檢測試劑盒的採用率不斷上升
    • 即時診斷檢測的成長
    • 人工智慧（AI）整合
  • 產業陷阱與挑戰
    • 進階診斷測試成本高昂
    • 缺乏標準化測驗指南
• 成長潛力分析
• 監管格局
• 報銷場景
• 技術格局
• 差距分析
• 波特的分析
• PESTEL 分析
• 價值鏈分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第 5 章：市場估計與預測：按診斷技術，2021 年至 2034 年

• 主要趨勢
• 血清學檢測
  • 酵素連結免疫吸附試驗
  • 蛋白質印跡法
• 核酸檢測
• 尿液抗原檢測
• 淋巴球轉化試驗
• 免疫螢光染色

第6章：市場估計與預測：依樣本類型，2021 – 2034 年

• 主要趨勢
• 血
• 尿
• 腦脊髓液
• 其他血液樣本

第 7 章：市場估計與預測：按病患類型，2021 – 2034 年

• 主要趨勢
• 成人
• 兒科

第 8 章：市場估計與預測：依最終用途，2021 年至 2034 年

• 主要趨勢
• 醫院
• 診斷實驗室
• 其他最終用途

第 9 章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：公司簡介

• bioMérieux
• Bio-Rad Laboratories
• Ceres Nanosciences
• DiaSorin
• Galaxy Diagnostics
• Gold Standard Diagnostics
• IGeneX
• Oxford Immunotec
• T2 Biosystems
• Thermo Fisher Scientific
• Trinity Biotech
• ZEUS Scientific

The Global Lyme Disease Testing Market is expected to reach USD 6.7 billion in 2024 and is projected to grow at a CAGR of 5.7% from 2025 to 2034. This growth is primarily driven by the increasing prevalence of Lyme disease in regions like North America and parts of Europe, where the infection is most common. Rising awareness of the serious long-term effects of untreated Lyme disease, such as neurological and musculoskeletal complications, has fueled the demand for early diagnosis and prompt treatment, further expanding the market.

Significant advancements in diagnostic technologies, including the widespread adoption of point-of-care (POC) tests and at-home testing kits, are reshaping the market. These innovative solutions offer quick and convenient diagnostic options that promote early detection and intervention, encouraging individuals to take action sooner. Public health initiatives and educational campaigns supported by government and health organizations have been crucial in raising awareness and advocating for regular testing. Additionally, the growing funding for research on tick-borne diseases is driving innovation and fueling further growth within the market.

In terms of diagnostic technology, the market is divided into several segments, including serological tests, nucleic acid tests, lymphocytic transformation tests, urine antigen testing, and immunofluorescent staining. The serological test segment is poised to experience the highest growth, with a projected CAGR of 6.2%, generating USD 5 billion by 2034. This growth is primarily attributed to the increasing adoption of serological tests, driven by technological advancements that have enhanced their reliability and effectiveness. Tests such as enzyme-linked immunosorbent assay (ELISA) and Western blot are highly effective at detecting Borrelia burgdorferi antibodies, securing their position as the most widely used and trusted method for Lyme disease detection.

The market is also categorized by sample type, including blood, urine, cerebrospinal fluid (CSF), and other blood-based samples. In 2024, the blood sample segment accounted for a 52.2% share of the market and is expected to maintain its dominant position throughout the forecast period. Blood samples are considered the gold standard for Lyme disease testing due to their high accuracy in detecting both antibodies and bacterial DNA. This makes them the preferred choice in clinical and laboratory settings, offering a simple and non-invasive diagnostic method.

In the U.S., the Lyme disease testing market, valued at USD 2.6 billion in 2024, is poised for strong growth during the forecast period. The high incidence of Lyme disease, combined with its geographical spread due to climate change and increased tick activity, is driving demand for testing services. Growing public awareness, supported by health organizations, is encouraging more proactive approaches to Lyme disease screening. As a result, healthcare providers are increasingly prioritizing Lyme disease testing, especially in high-risk areas, contributing to sustained market growth in the region.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of Lyme disease
    • 3.2.1.2 Advancements in diagnostic technologies
    • 3.2.1.3 Rising adoption of at-home test kits
    • 3.2.1.4 Growth in point-of-care testing
    • 3.2.1.5 Integration of artificial intelligence (AI)
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of advanced diagnostic tests
    • 3.2.2.2 Lack of standardized testing guidelines
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Reimbursement scenario
• 3.6 Technology landscape
• 3.7 Gap analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis
• 3.10 Value chain analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Diagnostic Technology, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Serological test
  • 5.2.1 ELISA
  • 5.2.2 Western blot
• 5.3 Nucleic acid test
• 5.4 Urine antigen testing
• 5.5 Lymphocytic transformation test
• 5.6 Immunofluorescent staining

Chapter 6 Market Estimates and Forecast, By Sample Type, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Blood
• 6.3 Urine
• 6.4 CSF
• 6.5 Other blood samples

Chapter 7 Market Estimates and Forecast, By Patient Type, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Adult
• 7.3 Pediatric

Chapter 8 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Diagnostic laboratories
• 8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 bioMérieux
• 10.2 Bio-Rad Laboratories
• 10.3 Ceres Nanosciences
• 10.4 DiaSorin
• 10.5 Galaxy Diagnostics
• 10.6 Gold Standard Diagnostics
• 10.7 IGeneX
• 10.8 Oxford Immunotec
• 10.9 T2 Biosystems
• 10.10 Thermo Fisher Scientific
• 10.11 Trinity Biotech
• 10.12 ZEUS Scientific